DE602006020139D1 - Heterocyclische spiro-verbindungen als aldosteronsynthaseinhibitoren - Google Patents

Heterocyclische spiro-verbindungen als aldosteronsynthaseinhibitoren

Info

Publication number
DE602006020139D1
DE602006020139D1 DE602006020139T DE602006020139T DE602006020139D1 DE 602006020139 D1 DE602006020139 D1 DE 602006020139D1 DE 602006020139 T DE602006020139 T DE 602006020139T DE 602006020139 T DE602006020139 T DE 602006020139T DE 602006020139 D1 DE602006020139 D1 DE 602006020139D1
Authority
DE
Germany
Prior art keywords
synthase inhibitors
aldosterone synthase
spiro compounds
heterocyclic spiro
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020139T
Other languages
English (en)
Inventor
Christoph Schumacher
Nathalie Jotterand
Christiane Marti
Aleksandar Stojanovic
Vincenzo Tschinke
Robert Mah
Peter Herold
Michael Quirmbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602006020139D1 publication Critical patent/DE602006020139D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602006020139T 2005-05-31 2006-05-30 Heterocyclische spiro-verbindungen als aldosteronsynthaseinhibitoren Active DE602006020139D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH9222005 2005-05-31
PCT/EP2006/062695 WO2006128852A2 (en) 2005-05-31 2006-05-30 Heterocyclic spiro-compounds as aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
DE602006020139D1 true DE602006020139D1 (de) 2011-03-31

Family

ID=37038333

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020139T Active DE602006020139D1 (de) 2005-05-31 2006-05-30 Heterocyclische spiro-verbindungen als aldosteronsynthaseinhibitoren

Country Status (15)

Country Link
US (1) US8071774B2 (de)
EP (1) EP1896481B1 (de)
JP (1) JP5007299B2 (de)
CN (1) CN101184760A (de)
AR (1) AR057040A1 (de)
AT (1) ATE498625T1 (de)
BR (1) BRPI0611313A2 (de)
CA (1) CA2609660A1 (de)
DE (1) DE602006020139D1 (de)
ES (1) ES2358275T3 (de)
IL (1) IL187647A0 (de)
PL (1) PL1896481T3 (de)
PT (1) PT1896481E (de)
TW (1) TW200716634A (de)
WO (1) WO2006128852A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049126A1 (es) * 2004-05-28 2006-06-28 Speedel Experimenta Ag Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
TW200813071A (en) 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
TW200904416A (en) 2007-03-29 2009-02-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
AR076706A1 (es) 2009-05-28 2011-06-29 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
MX2014000342A (es) 2011-07-08 2014-05-01 Novartis Ag Metodo para tratar la aterosclerosis en sujetos con alto nivel de trigliceridos.
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
KR20150119109A (ko) 2013-02-14 2015-10-23 노파르티스 아게 Nep (중성 엔도펩티다제) 억제제로서의 치환된 비스페닐 부타노익 포스폰산 유도체
TN2016000031A1 (en) 2013-07-25 2017-07-05 Novartis Ag Cyclic polypeptides for the treatment of heart failure
KR20160031552A (ko) 2013-07-25 2016-03-22 노파르티스 아게 합성 아펠린 폴리펩티드의 생체접합체
CU20170093A7 (es) 2015-01-23 2017-09-06 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
EP3887363A1 (de) 2018-11-27 2021-10-06 Novartis AG Zyklische pentamer-verbindungen als proprotein-konvertase-subtilisin-kexin-typ 9 (pcsk9)-inhibitoren zur behandlung von stoffwechselstörung
WO2020110011A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726505D0 (en) * 1987-11-12 1987-12-16 Ici Plc Naphtho(2 1-b)furan derivatives
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
JP4533139B2 (ja) * 2002-08-07 2010-09-01 ノバルティス アーゲー アルドステロン介在性病状の処置用剤としての有機化合物
JP2006508970A (ja) 2002-11-18 2006-03-16 ノバルティス アクチエンゲゼルシャフト イミダゾ［１，５ａ］ピリジン誘導体およびアルデステロンにより仲介される疾患の処置方法

Also Published As

Publication number Publication date
BRPI0611313A2 (pt) 2011-02-22
PT1896481E (pt) 2011-03-23
US20100010015A1 (en) 2010-01-14
EP1896481A2 (de) 2008-03-12
TW200716634A (en) 2007-05-01
EP1896481B1 (de) 2011-02-16
WO2006128852A2 (en) 2006-12-07
JP5007299B2 (ja) 2012-08-22
WO2006128852A3 (en) 2007-02-22
US8071774B2 (en) 2011-12-06
CA2609660A1 (en) 2006-12-07
PL1896481T3 (pl) 2011-07-29
CN101184760A (zh) 2008-05-21
JP2008542334A (ja) 2008-11-27
ATE498625T1 (de) 2011-03-15
AR057040A1 (es) 2007-11-14
ES2358275T3 (es) 2011-05-09
IL187647A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
ATE471939T1 (de) Heterocyclische spiro-verbindungen als aldosteronsynthaseinhibitoren
ATE498625T1 (de) Heterocyclische spiro-verbindungen als aldosteronsynthaseinhibitoren
ATE510832T1 (de) Heterocyclische verbindungen als c-fms- kinasehemmer
DE602006018506D1 (de) Als mikrobiozide geeignete heterocyclische amidderivate
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
NL2000397C2 (nl) Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
ATE479692T1 (de) Kondensierte imidazolderivate als aldosteronsynthaseinhibitoren
DE602008003015D1 (de) Heterocyclische spiroverbindungen
ATE510825T1 (de) Acylaminopyrazole als fgfr-inhibitoren
BRPI0718509A2 (pt) compostos orgânicos heterocíclicos
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE478064T1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE434618T1 (de) Spirozyklische verbindungen als hdac-hemmer
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE551342T1 (de) Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
ATE549340T1 (de) Spiroindolinon-derivate als mdm2-p53 inhibitoren
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE512953T1 (de) Heterocyclische verbindungen
EP2132211A4 (de) 4-cyanphenylamino-substituierte bizyklische und heterozyklische verbindungen als hiv-hemmer
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
BRPI0920239A2 (pt) compostos heterocíclicos como inibidores de proteínas quinases